Difference between revisions of "Penpulimab (Anniko)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Classical Hodgkin lymphoma]] | *[[Classical Hodgkin lymphoma]] | ||
| + | *[[Non-small cell lung cancer, squamous]] | ||
==History of changes in NMPA indication== | ==History of changes in NMPA indication== | ||
| Line 10: | Line 11: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' | + | *'''Code name:''' AK-105 |
| − | *'''Brand name:''' Anniko | + | *'''Generic name:''' pianprizumab |
| + | *'''Brand name:''' Anniko, Annikol | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 18: | Line 20: | ||
[[Category:Anti-PD-1 antibodies]] | [[Category:Anti-PD-1 antibodies]] | ||
[[Category:Classical Hodgkin lymphoma medications]] | [[Category:Classical Hodgkin lymphoma medications]] | ||
| + | [[Category:Non-small cell lung cancer, squamous medications]] | ||
[[Category:NMPA approved in 2021]] | [[Category:NMPA approved in 2021]] | ||
Latest revision as of 13:00, 8 September 2023
Mechanism of action
PD-1 inhibitor
Diseases for which it is used
History of changes in NMPA indication
- 2021-08-05: Initial approval for treatment of patients with relapsed or refractory ("r/r") classic Hodgkin’s lymphoma ("cHL") after at least second-line systemic chemotherapy treatment.
- 2023-01-15: Approved in combination with chemotherapy as the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC). (Based on AK105-302)
Also known as
- Code name: AK-105
- Generic name: pianprizumab
- Brand name: Anniko, Annikol